side effects of cagrilintide Effects: Risks and Warnings Cagrilintide: The Next-Gen Peptide for

Semaglutide (Wegovy, approved June 2021) and tirzepatide (Zepbound, approved November 2023) represent the current standard of care for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity [7][8]

This could possibly suggest that the peptide might be playing a role in enhancing the sensitivity of these lipolytic receptors, potentially making them more responsive to lipolytic stimuli

GHK-Cu also modulates the activity of growth factors such as TGF- and VEGF, which are critical for tissue repair

The evidence that does exist points to potential benefits in recovery, tissue repair, and inflammation modulation, but those are support functions, not fat-burning mechanisms